1. Mylan’s drug Fulphila represents the first biosimilar version of Amgen’s Neulasta, both of which boost white blood cell count to reduce infection risk in cancer patients undergoing chemotherapy.
2. Rituxan is the first treatment approved for moderate-to-severe pemphigus vulgaris, a rare autoimmune disease characterized by painful blistering on the skin and mucous membranes.
3. Mircera may now be used to treat chronic kidney disease-associated anemia in children.
More articles on supply chain:
How University of Washington Medical Center improved supply chain efficiency and saved $1M+
3 ways to understand healthcare supply chain in a changing market
Fitch: New drug approvals off pace from 2017
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
